RT Journal Article
T1 Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration.
A1 García-Layana, Alfredo
A1 Figueroa, Marta S
A1 Arias, Luis
A1 Araiz, Javier
A1 Ruiz-Moreno, José María
A1 García-Arumí, José
A1 Gómez-Ulla, Francisco
A1 López-Gálvez, María Isabel
A1 Cabrera-López, Francisco
A1 García-Campos, José Manuel
A1 Monés, Jordi
A1 Cervera, Enrique
A1 Armadá, Félix
A1 Gallego-Pinazo, Roberto
K1 Anticuerpos monoclonales humanizados
K1 Degeneración macular
K1 Factor A de crecimiento endotelial vascular
K1 Agudeza visual
K1 Degeneración macular húmeda
K1 Protocolos clínicos
K1 Recurrencia
K1 Humanos
AB Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the patient is treated in the presence of signs of lesion activity. Therefore, an early detection of reactivation of the disease with immediate retreatment is crucial to prevent visual acuity loss. Several trials suggest that "treat and extend" and other proactive regimens provide a reasonable approach. The rationale of the proactive regimens is to perform treatment anticipating relapses or recurrences and therefore avoid drops in vision while individualizing patient followup. Treat and extend study results in significant direct medical cost savings from fewer treatments and office visits compared to monthly treatment. Current data suggest that, for one year, PRN is less expensive, but treat and extend regimen would likely be less expensive for subsequent years. Once a patient is not a candidate to continue with treatment, he/she should be sent to an outpatient unit with adequate resources to follow nAMD patients in order to reduce the burden of specialized ophthalmologist services.
PB Hindawi Publishing Corporation
SN 2090-004X
YR 2015
FD 2015-11
LK http://hdl.handle.net/10668/2057
UL http://hdl.handle.net/10668/2057
LA en
NO García-Layana A, Figueroa MS, Arias L, Araiz J, Ruiz-Moreno JM, García-Arumí J, et al. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. J Ophthalmol; 2015:412903
NO Journal Article; Review;
DS RISalud
RD Apr 6, 2025